GRPH - Gene editing stocks gain after Eli Lilly deal amid FDA AdCom
2023-10-31 12:46:31 ET
More on Eli Lilly
- Albemarle Vs. Eli Lilly: 1 Potentially Set To Soar And 1 Bubble Stock To Ignore
- Eli Lilly: The GLP-1 Opportunity, While Increasingly Recognized, Is Vastly Underestimated
- Eli Lilly: Do Not Chase This Stock Over The Cliff
- Eli Lilly marks gene editing foray in deal with Beam
- Eli Lilly wins approval of first-in-class ulcerative colitis drug Omvoh
For further details see:
Gene editing stocks gain after Eli Lilly deal amid FDA AdCom